Patent ID: 6664442
Filing Date: 2003-12-16
Classification: A01K,C12Q

Abstract:
A method of selecting a compound effective in reducing inflammation associated with Alzheimer's Disease in a mammalian subject, comprisingsubjecting a non-human mammalian subject to a cerebral ischemic event characterized by elevation in an affected region of a marker selected from the group consisting of IL1&bgr;, TNF&agr;, MIP-1&agr;, GFAP, MHC II&agr;, MHC II Li, CD86, fractalkine and CX3CR1, administering to the test subject a test compound, selecting the test compound as effective in reducing inflammation associated with Alzheimer's Disease (AD) if an amount of the marker present in the affected region is significantly lower than an amount of marker protein present in an affected region in a control ischemic subject.